34 studies found for:    Open Studies | "Carcinoid Tumor"
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | "Carcinoid Tumor"
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Conditions: Metastatic Gastrointestinal Carcinoid Tumor;   Pulmonary Carcinoid Tumor;   Recurrent Gastrointestinal Carcinoid Tumor;   Recurrent Neuroendocrine Carcinoma of the Skin;   Regional Gastrointestinal Carcinoid Tumor;   Stage III Neuroendocrine Carcinoma of the Skin;   Stage IV Neuroendocrine Carcinoma of the Skin;   Thyroid Gland Medullary Carcinoma
Interventions: Drug: pazopanib hydrochloride;   Other: placebo;   Procedure: quality-of-life assessment;   Other: laboratory biomarker analysis
2 Recruiting Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer
Conditions: Adult Primary Hepatocellular Carcinoma;   Advanced Adult Primary Liver Cancer;   Endometrial Papillary Serous Carcinoma;   Localized Unresectable Adult Primary Liver Cancer;   Metastatic Gastrointestinal Carcinoid Tumor;   Ovarian Carcinosarcoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mixed Epithelial Carcinoma;   Ovarian Papillary Serous Carcinoma;   Pancreatic Alpha Cell Adenoma;   Pancreatic Alpha Cell Carcinoma;   Pancreatic Beta Islet Cell Adenoma;   Pancreatic Beta Islet Cell Carcinoma;   Pancreatic Delta Cell Adenoma;   Pancreatic Delta Cell Carcinoma;   Pancreatic G-cell Adenoma;   Pancreatic G-cell Carcinoma;   Pancreatic Polypeptide Tumor;   Pulmonary Carcinoid Tumor;   Recurrent Adult Primary Liver Cancer;   Recurrent Endometrial Carcinoma;   Recurrent Fallopian Tube Cancer;   Recurrent Gastrointestinal Carcinoid Tumor;   Recurrent Islet Cell Carcinoma;   Recurrent Ovarian Epithelial Cancer;   Recurrent Primary Peritoneal Cavity Cancer;   Regional Gastrointestinal Carcinoid Tumor;   Stage IIIA Endometrial Carcinoma;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Primary Peritoneal Cavity Cancer;   Stage IIIB Endometrial Carcinoma;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Primary Peritoneal Cavity Cancer;   Stage IIIC Endometrial Carcinoma;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Primary Peritoneal Cavity Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Primary Peritoneal Cavity Cancer;   Stage IVA Endometrial Carcinoma;   Stage IVB Endometrial Carcinoma;   Uterine Carcinosarcoma
Interventions: Drug: temsirolimus;   Biological: bevacizumab
3 Recruiting Natural History of Familial Carcinoid Tumor
Condition: Carcinoid
Intervention:
4 Recruiting Ziv-Aflibercept for Advanced Progressive Carcinoid Tumors
Condition: Carcinoid Tumor
Intervention: Drug: Ziv-aflibercept
5 Recruiting Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
Conditions: Carcinoid Tumor;   Pancreatic Neuroendocrine Tumor
Intervention: Drug: Cabozantinib
6 Recruiting A Study of Sunitinib Versus Placebo in Combination With Lanreotide in Patients With Progressive Advanced/Metastatic Midgut Carcinoid Tumors
Condition: Carcinoid Tumors
Interventions: Drug: Lanreotide;   Drug: Placebo (for sunitinib);   Drug: Sunitinib
7 Recruiting A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours
Conditions: Carcinoid Tumor of the Small Bowel;   Neuroendocrine Tumour
Interventions: Drug: Octreotide;   Drug: 177Lu-DOTA0-Tyr3-Octreotate
8 Not yet recruiting 68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors
Conditions: Neuroendocrine;   Neuroendocrine Tumor;   Neuroendocrine Cancer;   Neuroendocrine Carcinoma;   Carcinoid;   Carcinoid Tumor;   Islet Cell Tumor;   Apudoma
Intervention: Drug: 68Ga-DOTATATE will be given in tracer doses and injected intravenously to image tumors by Positron Emission Tomography.
9 Unknown  An Investigation of Small Intestinal Carcinoid Carcinoma in Families
Condition: Carcinoid Carcinoma
Intervention:
10 Unknown  Study Investigating MEN1 and SDHD in Familial Carcinoid Tumors
Condition: Carcinoid Neuroendocrine Cancer
Intervention:
11 Recruiting YF476 in Patients With Type II Gastric Carcinoids Associated With Zollinger-Ellison Syndrome
Condition: Carcinoid
Intervention: Drug: YF476
12 Unknown  RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid
Conditions: Pheochromocytoma;   Extra-Adrenal Paraganglioma;   Non-functioning Carcinoid
Intervention: Drug: RAD001
13 Recruiting Telotristat Etiprate for Carcinoid Syndrome Therapy
Condition: Carcinoid Syndrome
Interventions: Drug: Telotristat etiprate tablets (250 mg);   Drug: Placebo
14 Unknown  Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors
Conditions: Brain and Central Nervous System Tumors;   Gastrointestinal Carcinoid Tumor;   Islet Cell Tumor;   Neuroblastoma;   Pheochromocytoma;   Sarcoma;   Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Radiation: yttrium Y 90-edotreotide
15 Recruiting TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome)
Condition: Carcinoid Syndrome
Interventions: Drug: Telotristat etiprate tablets (250 mg);   Drug: Placebo tablets
16 Recruiting Doxorubicin Beads in Treating Patients With Unresectable Liver Metastases From Neuroendocrine Tumors
Conditions: Gastrointestinal Carcinoid Tumor;   Islet Cell Tumor;   Metastatic Cancer
Intervention: Drug: PVA microporous hydrospheres/doxorubicin hydrochloride
17 Recruiting Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms
Condition: Carcinoid Syndrome
Intervention: Drug: Telotristat etiprate tablets (250 mg)
18 Recruiting SwissNET - a Registry for Neuroendocrine Tumours in Switzerland
Conditions: Neuroendocrine Tumors;   Carcinoid Tumor
Intervention:
19 Recruiting RAMSETE: RAD001 in Advanced and Metastatic Silent Neuro-endocrine Tumors in Europe
Conditions: Carcinoma;   Neuroendocrine;   Non Functioning Neuroendocrine Tumors/NET;   Non Syndromic Neuroendocrine Tumors/NET;   Carcinoids;   Non Functioning
Intervention: Drug: Everolimus
20 Available 68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive Tumors
Conditions: Carcinoid Tumors;   Islet Cell (Pancreatic NET);   Other Neuroendocrine Tumors
Intervention: Drug: 68Ga-DOTA TATE

Previous Page Studies Shown (1-20) Next Page (21-34) Show next page of results
Indicates status has not been verified in more than two years